Study of YOLT-204 for transfusion-dependent beta-thalassemia
Part of Blood & lymphatic clinical trials.
This study tests an experimental medicine called YOLT-204 for people with beta-thalassemia who need regular blood transfusions. The goal is to see if this treatment is safe and if it might reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 35 years old.
- You must have a confirmed diagnosis of beta-thalassemia that requires regular blood transfusions.
- You must not have the most severe form of beta-thalassemia (called beta-zero).
- You should be fairly healthy overall, with normal heart, kidney, liver, and lung function.
- You must not have had a bone marrow transplant, gene therapy, or gene editing in the past.
- You must not have active infections or severe iron overload (iron buildup from transfusions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
This trial tests a new treatment called KL003 for people with beta-thalassemia who need regular blood transfusions. The treatment uses your own stem cells (collected from your blood) to try to reduce or stop the need for transfusions.
This study tests an experimental gene-editing treatment called CS-101 for people with severe beta-thalassemia who need regular blood transfusions. The goal is to see if it can reduce or eliminate the need for transfusions by helping the body make more healthy red blood cells.
Hear when a new Transfusion-dependent Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.